Lipopolysaccharide-binding protein and lipopolysaccharide receptor CD14 gene expression after thermal injury and its potential mechanism(s)

Journal of Trauma

Volumn 53, Issue 5, 2002, Pages 957-967

  Fang Catherine, W H ^a   Yao, Yong Ming ^a   Shi, Zhi Guo ^a   Yu, Yan ^a   Wu, Ye ^a   Lu, Lian Rong ^a   Sheng, Zhi Yong ^a  

^a 304TH HOSPITAL   (China)

Author keywords

Bacterial translocation; Burns; CD14; Cytokines; Endotoxin; Gene expression; Lipopolysaccharide; Lipopolysaccharide binding protein; Multiple organ dysfunction syndrome; Rats; Receptor; Tumor necrosis factor

Indexed keywords

CD14 ANTIGEN; LIPOPOLYSACCHARIDE BINDING PROTEIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL TRANSLOCATION; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; IMMUNOPATHOGENESIS; INFECTION RESISTANCE; INTESTINE; KIDNEY; LIVER; LUNG; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SCALD;

EID: 0036847809     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005373-200211000-00024     Document Type: Article

References (59)

1. Pisters PW, Pachter HL. Autologous splenic transplantation for splenic trauma. Ann Surg. 1994; 219; 225-235.
2. Cooney DR, Dearth JC, Swanson SE, Dewanjee MK, Telander RL. Relative merits of partial splenectomy, splenic reimplantation, and immunization in preventing postsplenectomy infection. Surgery. 1979; 86; 561-569.
3. Morris DH, Bullock FD. The importance of the spleen in resistance to infection. Ann Surg. 1919; LXX; 513-521.
4. King H, Schumacher HB., Splenic studies; I-susceptibility to infection after splenectomy in infancy. Ann Surg. 1952; 136; 239-242.
5. Krivit W. Overwhelming postsplenectomy infection. Am J Hematol. 1977; 2; 193-201.
6. Zarrabi MH, Rosner F. Pneumococcal sepsis and meningitis in vaccinated subjects; a review of 55 reported cases. J Natl Med Assoc. 1987; 79; 372-376.
7. Sullivan JL, Ochs HD, Schiffman G, et al. Immune response after splenectomy. Lancet. 1978; 1; 178-181.
8. Prevention of pneumococcal disease; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997; 46; 12-15.
9. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991; 325; 1453-1460.
10. Waghorn DJ. Overwhelming infection in asplenic patients; current best practice preventive measures are not being followed. J Clin Pathol. 2001; 54; 214-218.
11. Waghorn DL, Mayon-White RT. A study of 42 episodes of overwhelming post-splenectomy infection; is current guidance for asplenic individuals being followed? J Infect. 1997; 35; 289-294.
12. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy; an evaluation of current recommendations. JAMA. 1993; 270; 1826-1831.
13. Barbour ML. Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg Infect Dis. 1996; 2; 176-182.
14. Fernandez J, Levine OS, Sanchez J, et al. Prevention of Haemophilus influenzae type b colonization by vaccination; correlation with serum anti-capsular IgG concentration. J Infect Dis. 2000; 182; 1553-1556.
15. Hazlewood M, Nusrat R, Kumararatne DS, et al. The acquisition of anti-pneumococcal capsular polysaccharide, Haemophilus influenzae type b and tetanus toxoid antibodies with age, in the UK. Clin Exp Immunol. 1993; 93; 157-164.
16. Konradsen HB, Rasmussen C, Ejstrud P, Hansen JB. Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status. Epidemiol Infect. 1997; 119; 167-174.
17. O'Neal BJ, McDonald JC. The risk of sepsis in the asplenic adult. Ann Surg. 1981; 194; 775-778.
18. Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1993; 42 (RR-13) 8-10.
19. Recommendations of the Advisory Committee on Immunization Practices (ACIP); Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Morb Mortal Wkly Rep. 1993; 42 (RR-04); 1-18.
20. Prevention and control of meningococcal disease; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2000; 49 (RR-07) 1-3.
21. Barringer M, Meredith W, Starch M, Schiffman G, Meredith J, Beer F. Effect of anesthesia and splenectomy on antibody response to pneumococcal polysaccharide immunization. Am Surg. 1982; 48; 628-633.
22. Caplan ES, Boltansky H, Snyder MJ, et al. Response of traumatized splenectomized patients to immediate vaccination with polyvalent pneumococcal vaccine. J Trauma. 1983; 23; 801-805.
23. Pedersen FK, Nielsen JL, Andersen V, et al. Proposal for the prevention of fulminant infection after splenectomy. Ugeskr Laeger. 1992; 144; 1453-1456.
24. Ejstrud P, Hansen JB, Andreasen DA. Prophylaxis against pneumococcal infection after splenectomy; a challenge for hospitals and primary care. Eur J Surg. 1997; 163; 733-738.
25. Shatz DV, Schinsky MF, Pais LB, Romero-Steiner S, Kirton OC, Carlone GM. Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy. J Trauma. 1998; 44; 760-766.
26. Musher DM, Luchi MJ, Watson DA, Hamilton R, Braughn RE. Pneumococcal polysaccharide vaccine in young adults and older bronchitics; determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J Infect Dis. 1990; 161; 728-735.
27. Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol. 1997; 4; 415-422.
28. Nielsen SV, Sorensen UBS, Hendrichsen J. Antibodies against pneumococcal C-polysaccharide are not protective. Microb Pathog. 1993; 14; 299-305.
29. Wenger JD, Steiner SR, Pais LB, et al. Laboratory correlates for protective efficacy of pneumococcal vaccines; how can they be identified and validated? In; Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996; New Orleans, LA.
30. Vernacchio L, Romero-Steiner S, Martinez JE, et al. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. J Infect Dis. 2000; 181; 1162-1166.
31. Plikaytis BD, Goldblatt D, Frasch CE, et al. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study; multicenter study. J Clin Microbiol. 2000; 38; 2043-2050.
32. Conception NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2001; 8; 266-272.
33. Shatz DV, Romero-Steiner S, Elie C, Holder T, Carlone GM. Antibody responses at 14 and 28 days post-splenectomy in trauma patients receiving the 23-valent pneumococcal vaccine. J Trauma. 2002; 52; 194.
34. Mufson MA, Krause HE, Schiffman G. Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc Soc Exp Biol Med. 1983; 173; 270-275.
35. Mufson MA, Krause HE, Schiffman G, Hughey DF. Pneumococcal antibody levels one decade after immunization of healthy adults. Am J Med Sci. 1987; 293; 279-284.
36. Vella PR, McLean AA, Woodhour AF, Weibel RE, Hilleman MR. Persistence of pneumococcal antibodies in human subjects following vaccination. Proc Soc Exp Biol Med. 1980; 164; 435-438.
37. Giebink GS, Le CT, Schiffman G. Decline of serum antibody in splenectomized children after vaccination with pneumococcal capsular polysaccharides. J Pediatr. 1984; 105; 576-581.
38. Konradsen HB, Pedersen FK, Henrichsen J. Pneumococcal revaccination of splenectomized children. Pediatr Infect Dis J. 1990; 9; 258-263.
39. Konradsen HB, Nielsen JL, Pedersen FK, Henrichsen J. Antibody persistence in splenectomized adults after pneumococcal vaccination. Scand J Infect Dis. 1990; 22; 725-727.
40. Borgoc. JM, McLean AA, Vela PP, et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Biol Med. 1978; 157; 148-154.
41. Rutherford EJ, Livengood J, Higginbotham M, et al. Efficacy and safety of pneumococcal revaccination after splenectomy for trauma. J Trauma. 1995; 39; 448-452.
42. Mufson MA, Krause HE, Schiffman G. Reactivity and antibody responses of volunteers given two or three doses of pneumococcal vaccine. Proc Soc Exp Biol Med. 1984; 177; 220-225.
43. Kyhty H, Eskola J. New vaccines for the prevention of pneumococcal infections. Emerg Infect Dis. 1996; 2; 1-14.
44. Goebel W, Avery OT., Chemo-immunological studies conjugated carbohydrate proteins; I-the synthesis of p-aminophenol β-glucoside, p-aminophenol β-galactoside and their coupling with serum globulin. J Exp Med. 1929; 50; 521-533.
45. Moore FA, Moore EE, Moore GE, Millikan JS. Risk of splenic salvage after trauma; analysis of 200 adults. Am J Surg. 1984; 148; 800-805.
46. Tzoracoleftherakis E, Alivizatos V, Kalfarentzos F, Androulakis J. Complications of splenic tissue reimplantation. Ann R Coll Surg Engl. 1991; 73; 83-86.
47. Weber T, Hanisch E, Baum RP, Seufert RM. Late results of heterotopic autotransplantation of splenic tissue into the greater omentum. World J Surg. 1998; 22; 883-889.
48. Alwmark A, Bengmark S, Gullstrand P, Idvall I, Schalen C. Splenic resection or heterotopic transplantation of splenic tissue as alternatives to splenectomy; regeneration and protective effect against pneumococcal septicemia. Eur Surg Res. 1983; 15; 217-222.
49. Saxe JM, Hayward SR, Lucas CE, et al. Splenic reimplantation does not affect outcome in chronic canine model. Am Surg. 1994; 60; 674-680.
50. Budihna N, Milcinski M, Heberle J. Long-term follow-up after heterotopic splenic autotransplantation for traumatic splenic rupture. J Nucl Med. 1991; 32; 204-207.
51. Moore FA, Moore EE, Moore GE, Erdoes L. Fivefold enlargement of implants in a splenic autotransplant recipient. Surgery. 1993; 113; 462-465.
52. Ge Y, Gao H, Knog XT. Immunoglobulin and complement in splenectomised and autotransplanted subjects. Ann Med. 1989; 21; 265-267.
53. Leemans R, Manson W, Snijder JAM, et al. Immune response capacity after human splenic autotransplantation. Ann Surg. 1999; 229; 279-285.
54. Van Wyck DB, Witte MH, Witte CL, Strunk R. Humoral immunity in experimental hyposplenism. Surgery. 1978; 84; 134-139.
55. Van Wyck DB, Witte MH, Witte CL, Thies AC. Critical splenic mass for survival from experimental pneumococcemia. J Surg Res. 1980; 28; 14-17.
56. Cordazza GR, Tarozzi C, Vaira D, Frisoni M, Gasbarrini G. Return of splenic function after splenectomy; how much tissue is needed? BMJ. 1984; 289; 861-864.
57. Traub A, Gieink GS, Smith C, et al. Splenic reticuloendothelial function after splenectomy, spleen repair, and spleen autotransplantation. N Engl J Med. 1987; 317; 1559-1564.
58. Livingston CD, Levine BA, Sirinek KR. Site of splenic autotransplantation affects protection from sepsis. Am J Surg. 1983; 146; 734-737.
59. Thalhamer J, Leitner W, Kurz ME, Liaunigg A. Immunoarchitecture and specific functions of splenic autotransplants at different implantation sites. Eur Surg Res. 1992; 24; 22-36.